New diabetes drug aims to keep blood sugar in check for years

NCT ID NCT05366868

Ongoing Disease control Sponsor: National Center for Global Health and Medicine, Japan Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the diabetes pill imeglimin can control blood sugar longer than two other common drugs, metformin and vildagliptin. About 567 adults with type 2 diabetes will take one of these pills for up to 3 years. The goal is to see which drug keeps HbA1c (a measure of blood sugar) below 7% the longest without needing extra medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Imeglimin (a diabetes pill)
What this could lead to: If successful, imeglimin could offer a new option for long-term blood sugar control in type 2 diabetes, potentially delaying the need for additional medications.
What could go wrong: This is a Phase 4 trial comparing imeglimin to existing drugs, so it's not testing a new breakthrough. The benefit may be modest, and individual results vary. Side effects are possible, as with any diabetes medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Center Hospital of the National Center for Global Health and Medicine

Shinjuku-Ku, Tokyo, 162-8655, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.